Berkshire Hathaway stock may be set for a breakout on a strong 2026 insurance outlook, high yields, and bullish technicals.
Phased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented clinical results from pivotal Phase 3 RASolute 302 trial R ...
OptiCept Technologies AB (publ) has received trial data from its customer in Indonesia confirming that OptiBoost® treatment delivers significant improvements in rooting, survival and growth in challen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results